Chapter 1. Research Objective
1.1 Objective, Definition & Scope
1.2 Methodology
1.2.1 Primary Research
1.2.2 Secondary Research
1.2.3 Market Forecast - Estimation & Approach
1.2.4 Assumptions & Assessments
1.3 Insights and Growth - Relevancy Mapping
1.3.1 FABRIC Platform
1.4 Data mining & efficiency
Chapter 2. Executive Summary
2.1 Peptide Therapeutics Market Overview
2.2 Interconnectivity & Related markets
2.3 Ecosystem Map
2.4 Peptide Therapeutics Market Business Segmentation
2.5 Peptide Therapeutics Market Geographic Segmentation
2.6 Competition Outlook
2.7 Key Statistics
Chapter 3. Strategic Analysis
3.1 Peptide Therapeutics Market Revenue Opportunities
3.2 Cost Optimization
3.3 Covid19 aftermath - Analyst view
3.4 Peptide Therapeutics Market Digital Transformation
Chapter 4. Market Dynamics
4.1 DROC
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PEST Analysis
4.2.1 Political
4.2.2 Economic
4.2.3 Social
4.2.4 Technological
4.3 Market Impacting Trends
4.3.1 Positive Impact Trends
4.3.2 Adverse Impact Trends
4.4 Porter's 5-force Analysis
4.5 Market News - By Segments
4.5.1 Organic News
4.5.2 Inorganic News
Chapter 5. Market Segmentation
The Peptide Therapeutics Market has been analysed to include the below segmentation:
By Marketing Type
• Generic
• Branded
By Application
• Gastrointestinal Disorders
• Neurological Disorders
• Metabolic Disorders
• Cancer
• Other Applications
By Route of Administration
• Parenteral
• Oral
• Other Routes of Administration
Chapter 5A. Regional Segmentation
The Peptide Therapeutics Market has been analysed by studying the following regions:
North America
• By Marketing Type
• By Application
• By Route of Administration
Europe
• By Marketing Type
• By Application
• By Route of Administration
APAC
• By Marketing Type
• By Application
• By Route of Administration
LatAm
• By Marketing Type
• By Application
• By Route of Administration
MEA
• By Marketing Type
• By Application
• By Route of Administration
**The Regions are further studied to analyse the major countries within the respective regions. The coverage of the country level data is dynamic and is updated regularly based on the market movements. Normally, the countries covered in the report include:
• North America - United States, Canada, Mexico;
• Europe - United Kingdom, France, Italy, Germany, Spain, Rest of Europe;
• Asia Pacific - China, India, Japan, South Korea, Rest of APAC;
• Middle East & Africa - South Africa, GCC Countries, Rest of MEA;
• Latin America - Brazil, Argentina, Rest of LatAm;
Chapter 6. Market Use case studies
Chapter 7. KOL Recommendations
Chapter 8. Investment Landscape
8.1 Peptide Therapeutics Market Investment Analysis
8.2 Market M&A
8.3 Market Fund Raise & Other activity
Chapter 9. Peptide Therapeutics Market - Competitive Intelligence
9.1 Company Positioning Analysis
9.1.1 Positioning - By Revenue
9.1.2 Positioning - By Business Score
9.1.3 Legacy Positioning
9.2 Competitive Strategy Analysis
9.2.1 Organic Strategies
9.2.2 Inorganic Strategies
Chapter 10. Key Company Profiles
*The Peptide Therapeutics Market Report profiles companies based on the material impact they have on the market ecosystem. These are hence, to be read as 'Key Players' and not necessarily 'Market Leaders'.
Companies are typically profiled to include:
10.x.1 Company Fundamentals
10.x.2 Performance Overview
10.x.3 Product Overview
10.x.4 Recent Developments
Key Companies profiled in this report include:
• Eli Lilly and Company
• Amgen Inc.
• Pfizer Inc.
• Bristol-Myers Squibb
• EVER NEURO PHARMA GmbH
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceuticals Industries Ltd
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Novo Nordisk AS
Chapter 11. Appendix
11.1 About AllTheResearch (ATR)
11.2 ATR Services
11.3 Author details
11.4 Terms & Conditions
11.5 Contact us